SCHEDULE: BlackRock Boosts Stake in Fulcrum Therapeutics to 6.0%

BlackRock, Inc. has reported an increased beneficial ownership of 6.0% in Fulcrum Therapeutics Inc., holding 3,270,322 common shares as of September 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 3 to Schedule 13G, disclosing its beneficial ownership in FULCRUM THERAPEUTICS INC.
• As of September 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 3,270,322 shares of Common Stock.
• This represents 6.0% of the total outstanding Common Stock of FULCRUM THERAPEUTICS INC.
• BlackRock, Inc. holds sole voting power over 3,180,792 shares.
• BlackRock, Inc. holds sole dispositive power over 3,270,322 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities through which beneficial ownership is held, with at least one entity beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The filing indicates an increased institutional stake by BlackRock, which is generally viewed as a positive signal of confidence in the company. However, as a purely ownership disclosure, it provides no direct operational or financial performance data to assess a stronger sentiment.

Positives

• A major institutional investor like BlackRock, Inc. increasing its stake to 6.0% can signal confidence in Fulcrum Therapeutics Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist intent, which can be viewed positively by the market.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Fulcrum Therapeutics Inc.'s future performance or BlackRock's investment strategy beyond the certification of ordinary course business acquisition.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

BlackRock, as one of the world's largest asset managers, routinely discloses its significant holdings in publicly traded companies. Its investment in Fulcrum Therapeutics Inc., a biotechnology company, reflects its diversified portfolio strategy and its assessment of opportunities within the healthcare and life sciences sectors. Such institutional investments are common and contribute to market liquidity and price discovery.

Stakeholder Impact

• Shareholders: The increased stake by a prominent institutional investor like BlackRock may instill greater confidence among existing shareholders and potentially attract new investors, positively influencing market perception.

Key Dates

Recommendation

BlackRock's increased beneficial ownership to 6.0% in Fulcrum Therapeutics Inc. indicates continued institutional confidence. While this filing does not provide operational or financial performance details, a significant stake by a major asset manager like BlackRock can be viewed as a positive signal, suggesting a 'hold' recommendation for existing investors and further due diligence for potential new investors.

Keywords

Fulcrum Therapeutics, BlackRock, institutional ownership, beneficial ownership, Schedule 13G, common stock, investment management, biotechnology